Schizophrenia
Conditions
Keywords
schizophrenia, Estrogen receptor agonist, cognitive impairment, negative symptoms
Brief summary
The primary objectives of this application are to determine if the selective ERβ agonist LY500307, when added to antipsychotic medications, improves negative and/or cognitive symptoms in patients with schizophrenia. The specific hypotheses to be tested are to determine if LY500307 is safe and well tolerated in this population and whether it elicits a sufficient efficacy signal to be advanced for further testing in schizophrenia. A two-stage Phase 1b/Phase 2a adaptive (drop the inferior dose) experimental design is ongoing that combines three studies (clinical dose optimization, cortical target engagement confirmation and efficacy and safety assessment) into a single clinical trial. Stage 1 was conducted in year 1 and Stage 2 will be conducted in years 2 and 3. The goal of Stage 1 was to identify and advance the highest dose that did not demonstrate a safety signal and had target selectivity as determined by lack of TT suppression. This criteria was fulfilled at both doses, the larger of the two (75 mg/day dose) was advanced to Stage 2. Furthermore, there was no suggestion of ERα receptor activation (i.e., no pattern of TT decreases or feminization AEs) at either dose (25 mg/day and 75 mg/day). A third arm of 150 mg/day was added to Stage 2 for evaluation. Stage 2 results in the following three arms: placebo, 75 mg/day and 150 mg/day. The goals of Stage 2 are to further assess LY500307 doses for safety and target selectivity, confirm cortical target engagement and assess efficacy. Primary Aim 1: To determine if LY500307 demonstrates cortical target engagement as assessed by fMRI/N-back in frontal-parietal regions. Secondary measures of target engagement are fMRI episodic memory, Pseudo-Continuous Arterial Spin Labeling, Mismatch Negativity/evoked response potentials, Auditory Steady State Response, Auditory P300 and Quantitative EEG (QEEG). Primary Aim 2: To determine if LY500307 is superior to placebo for one or more of the primary efficacy endpoints: negative symptoms (Negative Symptom Assessment Scale - 16-item total score), working memory (the composite score for the Letter Number Sequencing and Spatial Span tests) and verbal memory (Hopkins Verbal Learning Test). Primary Aim 3: To determine if LY500307 reduces total testosterone (TT) plasma concentrations, which is indicative of loss of selectivity for ERβ and engagement of ERα, using the following criteria: Decrease in TT plasma concentrations of 50% from baseline in 50% of subjects per arm treated for two consecutive post-randomization values with LY500307 in Stage 1 and Stage 2 of the trial. Primary Aim 4: To assess the safety of LY500307 by determining if there are SAEs, AEs probably related to study drug, QTc prolongation, TT suppression (50% reduction from baseline) and to evaluate for other safety signals.
Interventions
DRUGLY500307 150mg
LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
DRUGLY500307 75mg
LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
DRUGPlacebo
6 placebo capsules daily for 8 weeks
DRUGLY500307 25mg
LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
Sponsors
Eli Lilly and Company
Indiana University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18 to 65 years of age at study entry * Male * DSM IV-TR diagnosis of schizophrenia as confirmed by Structured Clinical Interview for DSM-IV-TR (SCID) * Outpatient or inpatient status * Mild to moderate overall disease severity as defined by a CGI-S score of less than or equal to 4 (moderately ill) at randomization * Moderate levels of negative symptoms as defined by a PANSS negative symptom sub-score greater than or equal to 11. * Clinical stability as defined by: 1. No exacerbation of illness leading to an intensification of treatment in the opinion of the investigator within four weeks prior to randomization, and 2. No change in antipsychotic medication for at least four weeks prior to randomization
Exclusion criteria
* Subjects with current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, COPD, severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, or hepatic, renal gastroenterologic, respiratory, endocrinologic, neurologic, hematologic, or infectious diseases * Known or suspected history of prostate cancer, breast cancer, or other clinically significant neoplastic disease (other than squamous cell or basal cell carcinoma of skin) * Known or suspected history of deep venous thrombosis, stroke, venous thromboembolism, pulmonary embolism, paresis or paralysis that may be thrombogenic in origin * Subjects currently receiving testosterone replacement therapy or drugs that influence the hypothalamus-pituitary-gonadal axis. * Subjects who have clinically significant extrapyramidal signs (EPS) as defined by a score of \>20 on the Simpson-Angus Scale (SAS) * Clinically significant electrocardiogram (ECG) abnormality, including, but not limited to, a corrected QT interval (Bazett's; QTcB) \>450 msec. Repeat ECGs may be conducted at the discretion of the principal investigator. * Subjects with known medical history of Human Immunodeficiency Virus positive (HIV+) status * Subjects with an active seizure disorder * Subjects with implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, ventriculoperitoneal shunt, or other contraindication to undergoing an MRI scan * Known IQ less than 70 based on medical history * Current DSM IV-TR diagnosis of substance dependence (excluding caffeine and nicotine) * Subjects who test positive for (1) Hepatitis C virus antibody or (2) Hepatitis B surface antigen (HBsAg) with or without positive Hepatitis B core total antibody * Subjects with moderate to severe renal impairment as defined by creatinine clearance (CrCl) \< 60 ml/min (measured by the Cockcroft-Gault equation) at screening. Repeat evaluation may be conducted at the discretion of the Principal Investigator. * Subjects with hepatic impairment as defined by liver transaminases or total bilirubin \> 3 × upper limit of normal (ULN). Repeat evaluation may be conducted at the discretion of the Principal Investigator. * Subjects considered a high risk for suicidal acts - active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening * Subjects who have participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the four weeks prior to randomization OR subjects currently receiving treatment (within 1 dosing interval plus four weeks) with an investigational depot formulation of an antipsychotic medication * Subjects who demonstrate overtly aggressive behavior or who are deemed to pose a substantial risk of danger in the Investigator's opinion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Baseline, week 2, week 4, week 6, week 8 | The Negative Symptom Assessment Scale - 16-item (NSA-16) is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates subjects on 16 anchors, is a semi-structured, clinical interview, and each item is rated from 1 to 6. The total score is the sum of the 16 specific items and ranges from 16 to 96; a higher score indicates greater severity of illness. In addition, there is a global rating that represents the overall assessment of a subject's negative symptoms. The rating should not be an average of any particular behavior, but a gestalt of everything observed in the interview. |
| Working Memory Composite Score Changes | Baseline, week 2, week 4, week 6, week 8 | Working memory (composite score of the Wechsler Memory Scale-III: Spatial Span (WMS) and Letter Number Span (LNS) tests). WMS has 2 sections in which a subject recalls increasingly difficult sequences. The total raw score range for both sections is 0-32. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. LNS consists of 24 increasingly difficult sequences of letters and numbers that a subject is to recall and repeat back in Numeric-Alpha sequential order. The total raw score range is 0-24. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. The Working Memory composite score is calculated by summing the WMS and LNS tscores, ranging from 0-200, a higher tscore reflects better performance. |
| Verbal Learning Composite Score Changes | Baseline, week 2, week 4, week 6, week 8 | Verbal learning (composite score of the Hopkins Verbal Learning Test-Revised (HVLT-R)). The HVLT-R has 3 trials in which a subject recalls has many words from a list of 12 as they can. The total number recalled for each trial is summed and the score range is between 0-36. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. The verbal learning composite score is calculated by using the HVLT-R tscore, a higher tscore reflects better performance. |
| Number of Subjects With Total Testosterone Reduction | week 2, week 4, week 8 | Number of subjects with total testosterone reduction, as defined as a decrease in total testosterone plasma concentrations of 50% from baseline for two consecutive post-randomization values |
| Number of Subjects With QTc Prolongation | Week 4, Week 8 | Number of subjects with QTc prolongation, as defined as any subject with a change from baseline of 60 msec or greater during the active treatment phases |
| Cortical Target Engagement | Baseline, 8 weeks | To determine if LY500307 demonstrates cortical target engagement as assessed by changes in the N-back in frontal-parietal regions during the MRI. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks | 29 |
| LY500307 25mg LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks | 10 |
| LY500307 75mg LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks | 29 |
| LY500307 150mg LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks | 25 |
| Total | 93 |
Baseline characteristics
| Characteristic | LY500307 25mg | LY500307 75mg | LY500307 150mg | Placebo | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants | 29 Participants | 25 Participants | 29 Participants | 93 Participants |
| Age, Continuous | 36.64 years STANDARD_DEVIATION 12.58 | 37.15 years STANDARD_DEVIATION 13.67 | 37.64 years STANDARD_DEVIATION 10.21 | 36.28 years STANDARD_DEVIATION 12.27 | 37.07 years STANDARD_DEVIATION 12.18 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 17 Participants | 12 Participants | 17 Participants | 52 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 12 Participants | 13 Participants | 11 Participants | 38 Participants |
| Region of Enrollment United States | 10 participants | 29 participants | 25 participants | 29 participants | 93 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 10 Participants | 29 Participants | 25 Participants | 29 Participants | 93 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 29 | 0 / 10 | 0 / 29 | 0 / 27 |
| other Total, other adverse events | 4 / 29 | 1 / 10 | 3 / 29 | 7 / 25 |
| serious Total, serious adverse events | 1 / 29 | 0 / 10 | 0 / 29 | 1 / 25 |
Outcome results
Primary
Cortical Target Engagement
To determine if LY500307 demonstrates cortical target engagement as assessed by changes in the N-back in frontal-parietal regions during the MRI.
Time frame: Baseline, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LY500307 150mg | Cortical Target Engagement | Baseline | 0.15 beta coefficient | Standard Deviation 0.22 |
| LY500307 150mg | Cortical Target Engagement | Week 8 | 0.26 beta coefficient | Standard Deviation 0.21 |
| Placebo | Cortical Target Engagement | Week 8 | 0.22 beta coefficient | Standard Deviation 0.22 |
| Placebo | Cortical Target Engagement | Baseline | 0.16 beta coefficient | Standard Deviation 0.22 |
| LY500307 75mg | Cortical Target Engagement | Baseline | 0.27 beta coefficient | Standard Deviation 0.21 |
| LY500307 75mg | Cortical Target Engagement | Week 8 | 0.31 beta coefficient | Standard Deviation 0.26 |
| LY500307 25mg | Cortical Target Engagement | Baseline | 0.21 beta coefficient | Standard Deviation 0.2 |
| LY500307 25mg | Cortical Target Engagement | Week 8 | 0.30 beta coefficient | Standard Deviation 0.22 |
Primary
Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score
The Negative Symptom Assessment Scale - 16-item (NSA-16) is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates subjects on 16 anchors, is a semi-structured, clinical interview, and each item is rated from 1 to 6. The total score is the sum of the 16 specific items and ranges from 16 to 96; a higher score indicates greater severity of illness. In addition, there is a global rating that represents the overall assessment of a subject's negative symptoms. The rating should not be an average of any particular behavior, but a gestalt of everything observed in the interview.
Time frame: Baseline, week 2, week 4, week 6, week 8
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LY500307 150mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 6 | 43.43 score on a scale | Standard Deviation 15.36 |
| LY500307 150mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 2 | 40.96 score on a scale | Standard Deviation 12.82 |
| LY500307 150mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 8 | 42.90 score on a scale | Standard Deviation 14.09 |
| LY500307 150mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 4 | 41.35 score on a scale | Standard Deviation 12.38 |
| LY500307 150mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Baseline | 42.52 score on a scale | Standard Deviation 11.05 |
| Placebo | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 4 | 48.21 score on a scale | Standard Deviation 14.32 |
| Placebo | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 6 | 46.46 score on a scale | Standard Deviation 15.64 |
| Placebo | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 8 | 47.79 score on a scale | Standard Deviation 16.26 |
| Placebo | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 2 | 46.10 score on a scale | Standard Deviation 14.68 |
| Placebo | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Baseline | 45.34 score on a scale | Standard Deviation 12.03 |
| LY500307 75mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 4 | 45.30 score on a scale | Standard Deviation 12.16 |
| LY500307 75mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Baseline | 45.93 score on a scale | Standard Deviation 13.99 |
| LY500307 75mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 2 | 44.82 score on a scale | Standard Deviation 11.62 |
| LY500307 75mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 6 | 43.19 score on a scale | Standard Deviation 11.18 |
| LY500307 75mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 8 | 44.12 score on a scale | Standard Deviation 12.72 |
| LY500307 25mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 6 | 44.10 score on a scale | Standard Deviation 15.74 |
| LY500307 25mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 2 | 47.20 score on a scale | Standard Deviation 14.69 |
| LY500307 25mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Baseline | 46.10 score on a scale | Standard Deviation 12.6 |
| LY500307 25mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 4 | 45.80 score on a scale | Standard Deviation 13.41 |
| LY500307 25mg | Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score | Week 8 | 44.50 score on a scale | Standard Deviation 13.56 |
Primary
Number of Subjects With QTc Prolongation
Number of subjects with QTc prolongation, as defined as any subject with a change from baseline of 60 msec or greater during the active treatment phases
Time frame: Week 4, Week 8
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| LY500307 150mg | Number of Subjects With QTc Prolongation | Week 4 | 0 participants |
| LY500307 150mg | Number of Subjects With QTc Prolongation | Week 8 | 0 participants |
| Placebo | Number of Subjects With QTc Prolongation | Week 8 | 0 participants |
| Placebo | Number of Subjects With QTc Prolongation | Week 4 | 0 participants |
| LY500307 75mg | Number of Subjects With QTc Prolongation | Week 4 | 0 participants |
| LY500307 75mg | Number of Subjects With QTc Prolongation | Week 8 | 0 participants |
| LY500307 25mg | Number of Subjects With QTc Prolongation | Week 4 | 0 participants |
| LY500307 25mg | Number of Subjects With QTc Prolongation | Week 8 | 0 participants |
Primary
Number of Subjects With Total Testosterone Reduction
Number of subjects with total testosterone reduction, as defined as a decrease in total testosterone plasma concentrations of 50% from baseline for two consecutive post-randomization values
Time frame: week 2, week 4, week 8
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| LY500307 150mg | Number of Subjects With Total Testosterone Reduction | Week 8 | 0 participants |
| LY500307 150mg | Number of Subjects With Total Testosterone Reduction | Week 2 | 0 participants |
| LY500307 150mg | Number of Subjects With Total Testosterone Reduction | Week 4 | 0 participants |
| Placebo | Number of Subjects With Total Testosterone Reduction | Week 4 | 0 participants |
| Placebo | Number of Subjects With Total Testosterone Reduction | Week 2 | 0 participants |
| Placebo | Number of Subjects With Total Testosterone Reduction | Week 8 | 0 participants |
| LY500307 75mg | Number of Subjects With Total Testosterone Reduction | Week 8 | 0 participants |
| LY500307 75mg | Number of Subjects With Total Testosterone Reduction | Week 2 | 0 participants |
| LY500307 75mg | Number of Subjects With Total Testosterone Reduction | Week 4 | 0 participants |
| LY500307 25mg | Number of Subjects With Total Testosterone Reduction | Week 4 | 0 participants |
| LY500307 25mg | Number of Subjects With Total Testosterone Reduction | Week 2 | 0 participants |
| LY500307 25mg | Number of Subjects With Total Testosterone Reduction | Week 8 | 0 participants |
Primary
Verbal Learning Composite Score Changes
Verbal learning (composite score of the Hopkins Verbal Learning Test-Revised (HVLT-R)). The HVLT-R has 3 trials in which a subject recalls has many words from a list of 12 as they can. The total number recalled for each trial is summed and the score range is between 0-36. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. The verbal learning composite score is calculated by using the HVLT-R tscore, a higher tscore reflects better performance.
Time frame: Baseline, week 2, week 4, week 6, week 8
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LY500307 150mg | Verbal Learning Composite Score Changes | Week 8 | 34.67 score on a scale | Standard Deviation 5.63 |
| LY500307 150mg | Verbal Learning Composite Score Changes | Week 4 | 33.96 score on a scale | Standard Deviation 7.04 |
| LY500307 150mg | Verbal Learning Composite Score Changes | Week 2 | 34.17 score on a scale | Standard Deviation 6.97 |
| LY500307 150mg | Verbal Learning Composite Score Changes | Week 6 | 33.74 score on a scale | Standard Deviation 6.78 |
| LY500307 150mg | Verbal Learning Composite Score Changes | Baseline | 33.36 score on a scale | Standard Deviation 6.6 |
| Placebo | Verbal Learning Composite Score Changes | Baseline | 33.93 score on a scale | Standard Deviation 5.98 |
| Placebo | Verbal Learning Composite Score Changes | Week 8 | 35.54 score on a scale | Standard Deviation 7.57 |
| Placebo | Verbal Learning Composite Score Changes | Week 2 | 35.41 score on a scale | Standard Deviation 8.73 |
| Placebo | Verbal Learning Composite Score Changes | Week 4 | 35.11 score on a scale | Standard Deviation 7.43 |
| Placebo | Verbal Learning Composite Score Changes | Week 6 | 34.44 score on a scale | Standard Deviation 7.84 |
| LY500307 75mg | Verbal Learning Composite Score Changes | Week 4 | 37.42 score on a scale | Standard Deviation 8.26 |
| LY500307 75mg | Verbal Learning Composite Score Changes | Baseline | 34.50 score on a scale | Standard Deviation 7.39 |
| LY500307 75mg | Verbal Learning Composite Score Changes | Week 8 | 37.12 score on a scale | Standard Deviation 7.76 |
| LY500307 75mg | Verbal Learning Composite Score Changes | Week 2 | 37.11 score on a scale | Standard Deviation 8.22 |
| LY500307 75mg | Verbal Learning Composite Score Changes | Week 6 | 34.62 score on a scale | Standard Deviation 7.13 |
| LY500307 25mg | Verbal Learning Composite Score Changes | Week 8 | 37.30 score on a scale | Standard Deviation 6.17 |
| LY500307 25mg | Verbal Learning Composite Score Changes | Week 2 | 34.20 score on a scale | Standard Deviation 4.87 |
| LY500307 25mg | Verbal Learning Composite Score Changes | Week 4 | 34.60 score on a scale | Standard Deviation 5.52 |
| LY500307 25mg | Verbal Learning Composite Score Changes | Week 6 | 33.40 score on a scale | Standard Deviation 6.28 |
| LY500307 25mg | Verbal Learning Composite Score Changes | Baseline | 32.30 score on a scale | Standard Deviation 6.63 |
Primary
Working Memory Composite Score Changes
Working memory (composite score of the Wechsler Memory Scale-III: Spatial Span (WMS) and Letter Number Span (LNS) tests). WMS has 2 sections in which a subject recalls increasingly difficult sequences. The total raw score range for both sections is 0-32. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. LNS consists of 24 increasingly difficult sequences of letters and numbers that a subject is to recall and repeat back in Numeric-Alpha sequential order. The total raw score range is 0-24. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. The Working Memory composite score is calculated by summing the WMS and LNS tscores, ranging from 0-200, a higher tscore reflects better performance.
Time frame: Baseline, week 2, week 4, week 6, week 8
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LY500307 150mg | Working Memory Composite Score Changes | Week 6 | 37.13 score on a scale | Standard Deviation 11.43 |
| LY500307 150mg | Working Memory Composite Score Changes | Week 2 | 35.70 score on a scale | Standard Deviation 10.68 |
| LY500307 150mg | Working Memory Composite Score Changes | Week 8 | 37.86 score on a scale | Standard Deviation 11.24 |
| LY500307 150mg | Working Memory Composite Score Changes | Week 4 | 35.30 score on a scale | Standard Deviation 13.08 |
| LY500307 150mg | Working Memory Composite Score Changes | Baseline | 34.76 score on a scale | Standard Deviation 12.03 |
| Placebo | Working Memory Composite Score Changes | Week 4 | 35.93 score on a scale | Standard Deviation 12.14 |
| Placebo | Working Memory Composite Score Changes | Week 6 | 36.00 score on a scale | Standard Deviation 10.99 |
| Placebo | Working Memory Composite Score Changes | Week 8 | 38.04 score on a scale | Standard Deviation 13.08 |
| Placebo | Working Memory Composite Score Changes | Week 2 | 36.41 score on a scale | Standard Deviation 12.55 |
| Placebo | Working Memory Composite Score Changes | Baseline | 33.21 score on a scale | Standard Deviation 11.86 |
| LY500307 75mg | Working Memory Composite Score Changes | Week 4 | 37.54 score on a scale | Standard Deviation 8.66 |
| LY500307 75mg | Working Memory Composite Score Changes | Baseline | 34.79 score on a scale | Standard Deviation 10.9 |
| LY500307 75mg | Working Memory Composite Score Changes | Week 2 | 36.89 score on a scale | Standard Deviation 8.94 |
| LY500307 75mg | Working Memory Composite Score Changes | Week 6 | 38.54 score on a scale | Standard Deviation 9.63 |
| LY500307 75mg | Working Memory Composite Score Changes | Week 8 | 37.48 score on a scale | Standard Deviation 9.18 |
| LY500307 25mg | Working Memory Composite Score Changes | Week 6 | 37.20 score on a scale | Standard Deviation 13.37 |
| LY500307 25mg | Working Memory Composite Score Changes | Week 2 | 36.50 score on a scale | Standard Deviation 13.09 |
| LY500307 25mg | Working Memory Composite Score Changes | Baseline | 35.70 score on a scale | Standard Deviation 14.88 |
| LY500307 25mg | Working Memory Composite Score Changes | Week 4 | 35.90 score on a scale | Standard Deviation 13.49 |
| LY500307 25mg | Working Memory Composite Score Changes | Week 8 | 38.00 score on a scale | Standard Deviation 12.27 |